JGC
CPIX icon

J. Goldman & Co’s Cumberland Pharmaceuticals CPIX Stock Holding History

J. Goldman & Co’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-81,040
Closed -$263K – 743
2026
Q1 		$263K Sell
81,040
-13,501
-14% -$52K 0.01% 579
2025
Q4 		$376K Sell
94,541
-113,602
-55% -$337K 0.01% 477
2025
Q3 		$649K Sell
208,143
-12,564
-6% -$41.7K 0.02% 365
2025
Q2 		$739K Sell
220,707
-20,774
-9% -$98.4K 0.02% 356
2025
Q1 		$1.02M Buy
+241,481
New +$1M 0.03% 363

Other funds holding CPIX

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

J. Goldman & Co's CPIX Position: Q2 2026 in Review

J. Goldman & Co sold out of Cumberland Pharmaceuticals (CPIX) in Q2 2026, closing a stake of 81,040 shares — an estimated $263K sold.

J. Goldman & Co first reported a position in CPIX in Q1 2025 and held it in 5 quarters. The position peaked at $1.02M in Q1 2025. 32 funds tracked by Wall St. Rank hold CPIX as of Q2 2026.

  • J. Goldman & Co reported no remaining Cumberland Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 81,040 Cumberland Pharmaceuticals shares in Q2 2026, an estimated $263K.
  • J. Goldman & Co first reported a position in Cumberland Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • J. Goldman & Co's Cumberland Pharmaceuticals position peaked at $1.02M in Q1 2025.
  • 32 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.